Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental leishmania major infection

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3632-3643

  Pandey, Surya Prakash ^a   Chandel, Himanshu Singh ^a   Srivastava, Sunit ^a   Selvaraj, Sathishkumar ^a   Jha, Mukesh Kumar ^a   Shukla, Divanshu ^a   Ebensen, Thomas ^b   Guzman, Carlos A ^b   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LENTIVIRUS VECTOR; LIPOPEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE SYNTHASE; PEGYLATED BISACYCLOXYPROPYLCYSTEINE VACCINE; PEPTIDE VACCINE; PEPTIDOGLYCAN; PLACEBO; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR ELK 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, MOUSE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND; MACROGOL DERIVATIVE; NOS2 PROTEIN, MOUSE; PAM(3)CSK(4) PEPTIDE; S (2,3 BISPALMITOYLOXYPROPYL) CYSTEINYL AMIDO MONOMETHOXYL POLYETHYLENE GLYCOL; S-(2,3-BISPALMITOYLOXYPROPYL)-CYSTEINYL-AMIDO-MONOMETHOXYL POLYETHYLENE GLYCOL; TLR2 PROTEIN, MOUSE; TLR6 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE COUNT; MACROPHAGE; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PARASITOLOGY; PATHOLOGY; PERITONEUM MACROPHAGE; SKIN LEISHMANIASIS;

ANIMALS; CYTOKINES; GENE EXPRESSION REGULATION; HEPATOCYTE NUCLEAR FACTOR 1-BETA; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIGANDS; LIPOPEPTIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTOR 9;

EID: 84907221138     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400672     Document Type: Article

References (58)

1. Matsumoto, C. , T. Oda, S. Yokoyama, T. Tominari, M. Hirata, C. Miyaura, and M. Inada. 2012. Toll-like receptor 2 heterodimers, TLR2/6 and TLR2/1 induce prostaglandin E production by osteoblasts, osteoclast formation and inflammatory periodo ntitis. Biochem. Biophys. Res. Commun. 428: 110-115.
2. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
3. Sheedy, F. J., and L. A. O'Neill. 2007. The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling. J. Leukoc. Biol. 82: 196-203.
4. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082.
5. Kang, J. Y., X. Nan, M. S. Jin, S. J. Youn, Y. H. Ryu, S. Mah, S. H. Han, H. Lee, S. G. Paik, and J. O. Lee. 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873-884.
6. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680.
7. Medzhitov, R., and C. A. Janeway, Jr. 1997. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9: 4-9.
8. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macr ophage activation. Nat. Rev. Immunol. 8: 958-969.
9. Sacks, D., and C. Anderson. 2004. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol. Rev. 201: 225-238.
10. Frankenburg, S., V. Leibovici, N. Mansbach, S. J. Turco, and G. Rosen. 1990. Effect of glycolipids of Leishmania parasites on human monocyte activity: inhibition by lipophosphoglycan. J. Immunol. 145: 4284-4289.
11. Srivastava, S., S. P. Pandey, M. K. Jha, H. S. Chandel, and B. Saha. 2013. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to de crease TLR-9 expression and reduce anti-leishmanial responses. Clin. Exp. Immunol. 172: 403-409.
12. Vargas-Inchaustegui, D. A., W. Tai, L. Xin, A. E. Hogg, D. B. Corry, and L. Soong. 2009. Di stinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect. Immun. 77: 2948-2956.
13. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544.
14. Chandra, D., and S. Naik. 2008. Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin. Exp. Immunol. 154: 224-234.
15. de Almeida, L. A., G. C. Macedo, F. A. Marinho, M. T. Gomes, P. P. Corsetti, A. M. Silva, J. Cassataro, G. H. Giambartolomei, and S. C. Oliveira. 2013. Tolllike receptor 6 plays an important role in host innate resistance to Bru cella abortus infection in mice. Infect. Immun. 81: 1654-1662.
16. Marinho, F. A., R. R. de Paula, A. C. Mendes, L. A. de Almeida, M. T. Gomes, N. B. Carvalho, F. S. Oliveira, M. V. Caliari, and S. C. Oliveira. 2013. Toll-like receptor 6 senses Mycobacterium avium and is required for efficient control of mycobacterial infection. Eur. J. Immunol. 43: 2373-2385.
17. Rubino, I., A. Coste, D. Le Roy, T. Roger, K. Jaton, M. Boeckh, M. Monod, J. P. Latgé, T. Calandra, and P. Y. Bochud. 2012. Species-specific recognition of Aspergillus fumigatus by Toll-like receptor 1 and Toll-like receptor 6. J. Infect. Dis . 205: 944-954.
18. Tuvim, M. J., B. E. Gilbert, B. F. Dickey, and S. E. Evans. 2012. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 7: e30596.
19. Schneider, C., T. Schmidt, C. Ziske, K. Tiemann, K. M. Lee, V. Uhlinsky, P. Behrens, T. Sauerbruch, I. G. Schmidt-Wolf, P. F. Mühlradt, et al. 2004. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53: 355-361.
20. Weigt, H., P. F. Muhlradt, M. Larbig, N. Krug, and A. Braun. 2004. The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFNgamma to reverse the Th2 skew in an in vitro allergy model. J. Immunol. 172: 6080-6086.
21. Knothe, S., V. Mutschler, S. Rochlitzer, C. Winkler, T. Ebensen, C. A. Guzman, J. Hohlfeld, A. Braun, and M. Muller. 2011. Local treatment with BPPcysMPEG reduces allergic airway inflammation in sensitized mice. Immunobiology 216: 11 0-117.
22. Constantinescu, C. S., B. D. Hondowicz, M. M. Elloso, M. Wysocka, G. Trinchieri, and P. Scott. 1998. The role of IL-12 in the maintenance of an established Th1 immune response in experimental l eishmaniasis. Eur. J. Immunol. 28: 2227-2233.
23. Murray, H. W., Y. Zhang, Y. Zhang, V. S. Raman, S. G. Reed, and X. Ma. 2013. Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect. Immun. 81: 2318-2326.
24. Suffia, I., S. K. Reckling, G. Salay, and Y. Belkaid. 2005. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 174: 5444-5455.
25. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
26. Bodas, M., N. Jain, A. Awasthi, S. Martin, R. K. Penke Loka, D. Dandekar, D. Mitra, and B. Saha. 2006. Inhibition of IL-2 induc ed IL-10 production as a principle of phase-specific immunotherapy. J. Immunol. 177: 4636-4643.
27. Martin, S., S. Pahari, R. Sudan, and B. Saha. 2010. CD40 signaling in CD8+ CD40+ T cells turns on contra-T regulatory cell functions. J. Immunol. 184: 5510-5518.
28. Martin, S., R. Agarwal, G. Murugaiyan, and B. Saha. 2010. CD40 expression levels modulate regulatory T cells in Leishmania donovani infection. J. Immunol. 185: 551-559.
29. Chen, Q., T. S. Davidson, E. N. Huter, and E. M. Shevach. 2009. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J. Immunol. 183: 4458-4466.
30. Zanin-Zhorov A.,I.R. Cohen., 2013, Signaling via TLR2 and TLR4 directly down-regulates T cell effector functions: the regulatory face of danger signals, Front. Immunol., 4, 211.
31. Wadhone, P., M. Maiti, R. Agarwal, V. Kamat, S. Martin, and B. Saha. 2009. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 182: 7146-7154.
32. Srivastava, N., R. Sudan, and B. Saha. 2011. CD4 0-modulated dual-specificity phosphatases MAPK phosphatase (MKP)-1 and MKP-3 reciprocally regulate Leishmania major infection. J. Immunol. 186: 5863-5872.
33. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2007. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 178: 2047-2055.
34. Awasthi, A., R. Mathur, A. Khan, B. N. Joshi, N. Jain, S. Sawant, R. Boppana, D. Mitra, and B. Saha. 2003. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a hostprotective memory T cell response. J. Exp. Med. 197: 1037-1043.
35. Liese, J., U. Schleicher, and C. Bogdan. 2008. The innate immune response against Leishmania parasites. Immunobiology 213: 377-387.
36. Tuon, F. F., V. S. Amato, H. A. Bacha, T. Almusawi, M. I. Duarte, and V. Amato Neto. 2008. Toll-like receptors and leishmaniasis. Infect. Immun. 76: 866-872.
37. Flandin, J. F., F. Chano, and A. De scoteaux. 2006. RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur. J. Immunol. 36: 411-420.
38. Ives, A., C. Ronet, F. Prevel, G. Ruzzante, S. Fuertes-Marraco, F. Schutz, H. Zangger, M. Revaz-Breton, L. F. Lye, S. M. Hickerson, et al. 2011. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. S cience 331: 775-778.
39. Schamber-Reis, B. L., P. M. Petritus, B. C. Caetano, E. R. Martinez, K. Okuda, D. Golenbock, P. Scott, and R. T. Gazzinelli. 2013. UNC93B1 and nucleic acidsens ing Toll-like receptors mediate host resistance to infection with Leishmania major. J. Biol. Chem. 288: 7127-7136.
40. Kropf, P., M. A. Freudenberg, M. Modolell, H. P. Price, S. Herath, S. Antoniazi, C. Galanos, D. F. Smith, and I. Muller. 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 72: 1920-1928.
41. Abou Fakher, F. H., N. Rachinel, M. Klimczak, J. Louis, and N. Doyen. 2009. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J. Immunol. 182: 1386-1396.
42. Liese, J., U. Schleicher, and C. Bogdan. 2007. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur. J. Immunol. 37: 3424-3434.
43. Bogdan, C., M. Rö llinghoff, and A. Diefenbach. 2000. The role of nitric oxide in innate immunity. Immunol. Rev. 173: 17-26.
44. Gay, N. J., and M. Gangloff . 2007. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76: 141-165.
45. Arthur, J. S., and S. C. Ley. 2013. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13: 679-692.
46. Kyriakis, J.M., and J. Avruch. 2012.Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92: 689-737.
47. Felonato, M., A. Pina, E. F. de Araujo, F. V. Loures, S. B. Bazan, C. Feriotti, and V. L. Calich. 2012. Anti-CD25 treatment depletes Treg cells and decreases disease severity in susceptible and resi stant mice infected with Paracoccidioides brasiliensis. PLoS One 7: e51071.
48. Ghosh, J., S. Das, R. Guha, D. Ghosh, K. Naskar, A. Das, and S. Roy. 2012. Hyperlipidemia offers protection against L eishmania donovani infection: role of membrane cholesterol. J. Lipid Res. 53: 2560-2572.
49. Schenk, M., J. T. Belisle, and R. L. Modlin. 2009. TLR2 looks at lipoproteins. Immunity 31: 847-849.
50. Gupta, S., D. Campbell, B. Dérijard, and R. J. Davis. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393.
51. Kole L.,B. Giri,S. K. Manna,B. Pal,S. Ghosh., 2011. Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phospho rylation and blocking NFkB nuclear translocation. Eur. J. Pharmacol., 653, 8-15.
52. Reimold, A. M., J. Kim, R. Finberg, and L. H. Glimcher. 2001. Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int. Immunol. 13: 241-248.
53. Gille, H., M. Kortenjann, O. Thomae, C. Moomaw, C. Slaughter, M. H. Cobb, and P. E. Shaw. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14: 951-962.
54. Gille, H., A. D. Sharrocks, and P. E. Shaw. 1992. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414-417.
55. Fuchs, B., S. Knothe, S. Rochlitzer, M. Nassimi, M. Greweling, H. D. Lauenstein, C. Nassenstein, M. Muller, T. Ebensen, A. M. Dittrich, et al. 2010. A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitization to Timothy grass pollen antigen s. Int. Arch. Allergy Immunol. 152: 131-139.
56. Stetson, D. B., M. Mohrs, V. Mallet-Designe, L. Teyton, and R. M. Locksley. 2002. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity 17: 191-200.
57. Prajeeth, C. K., A. C. Jirmo, J. K. Krishnaswamy, T. Ebensen, C. A. Guzman, S. Weiss, H. Constabel, R. E. Schmidt, and G. M. Behr ens. 2010. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against coadministered and linked antigens. Eur. J. Immunol. 40: 1272-1283.
58. Li, C., P. J. Ebert, and Q. J. Li. 2 013. T cell receptor (TCR) and transforming growth factor b (TGF-b) signaling converge on DNA (cytosine-5)-methyltransferase to control forkhead box protein 3 (foxp3) locus methylation and inducible regulatory T cell differentiation. J. Biol. Chem. 2 88: 19127-19139